Skip to main content

Fiscal Wizard · Single-issue tearsheet

CAI / Jun 21, 2026 Run #7462

CAI

Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Composite verdict

F 29.3 / 100
Bearish setup · Mean Reversion 14 drivers · 2 gates blocking
  • Accumulation/Distribution Line
  • Williams %R
  • Stochastic Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 176th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 35Mean-reversion Bearish 16

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -87%
Asset value $2.04Earnings power value $2.88Price $18.47

Priced above its no-growth earnings power value ($2.88/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

58.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Cash Conversion Cycle 4
Asset Turnover 100
Free Cash Flow Yield 4

Technicals Bearish

0.2 / 100

Bearish setup leads (Accumulation/Distribution Line, Williams %R, Stochastic Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Williams %R 9
Accumulation/Distribution Line 12
Stochastic Cross 14

Risk Gates

2 blocking 8 caution

2 guards active, 18 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for CAI.